A5050333678- Multiple Myeloma Research and Treatments
- Cancer Treatment and Pharmacology
- Protein Degradation and Inhibitors
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Developmental Biology and Gene Regulation
- Cancer therapeutics and mechanisms
- Muscle Physiology and Disorders
- Bone health and treatments
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Congenital heart defects research
- Blood disorders and treatments
- Histone Deacetylase Inhibitors Research
- Lymphoma Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- Hematopoietic Stem Cell Transplantation
- Zebrafish Biomedical Research Applications
- Immunotherapy and Immune Responses
- Hematological disorders and diagnostics
- Radiopharmaceutical Chemistry and Applications
- Hemoglobinopathies and Related Disorders
- Monoclonal and Polyclonal Antibodies Research
- Cell Image Analysis Techniques
King's College London
2014-2024
US Biologic (United States)
2023-2024
Salus (United States)
2023-2024
Guy's Hospital
2012-2023
NexImmune (United States)
2021-2023
Sorrento Therapeutics (United States)
2019-2021
King's College - North Carolina
2021
Chadron State College
2014-2018
Bristol-Myers Squibb (Switzerland)
2006-2017
Roswell Park Comprehensive Cancer Center
2017
Lenalidomide is a structural analogue of thalidomide with similar but more potent biologic activity. This phase 3, placebo-controlled trial investigated the efficacy lenalidomide plus dexamethasone in treatment relapsed or refractory multiple myeloma.Of 351 patients who had received at least one previous antimyeloma therapy, 176 were randomly assigned to receive 25 mg oral and 175 placebo on days 1 21 28-day cycle. In addition, all 40 4, 9 12, 17 20 for first four cycles subsequently, after...
Severe, often refractory anemia is characteristic of the myelodysplastic syndrome associated with chromosome 5q31 deletion. We investigated whether lenalidomide (CC5013) could reduce transfusion requirement and suppress abnormal 5q31- clone in patients this disorder.One hundred forty-eight received 10 mg for 21 days every 4 weeks or daily. Hematologic, bone marrow, cytogenetic changes were assessed after 24 treatment by an intention-to-treat analysis.Among 148 patients, 112 had a reduced...
Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, clinical activity in relapsed or refractory multiple myeloma.Patients the United States and Canada who had received at least one previous therapy for myeloma required additional treatment were randomly assigned receive either 25 mg of lenalidomide placebo on days 1 21 28-day cycle. Both groups also 40 dexamethasone 4, 9 12, 17 20 first four cycles. After fourth cycle, was...
Skeletal complications are a major clinical manifestation of multiple myeloma. These caused by soluble factors that stimulate osteoclasts to resorb bone. Bisphosphonates such as pamidronate inhibit osteoclastic activity and reduce bone resorption.Patients with stage III myeloma at least one lytic lesion received either placebo or (90 mg) four-hour intravenous infusion given every four weeks for nine cycles in addition antimyeloma therapy. The patients were stratified according whether they...
Bisphosphonates such as pamidronate disodium inhibit osteoclast-induced bone resorption associated with cancer that has metastasized to bone.
Ineffective erythropoiesis is the hallmark of myelodysplastic syndromes. Management anemia caused by ineffective difficult. In patients with syndromes and symptomatic anemia, we evaluated safety hematologic activity lenalidomide, a novel analogue thalidomide.Forty-three transfusion-dependent or received lenalidomide at doses 25 10 mg per day for 21 days every 28-day cycle. All either had no response to recombinant erythropoietin high endogenous level low probability benefit from such...
The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant prospective comparison two approaches.We randomly assigned 1623 to in 28-day cycles until disease progression (535 patients), same 72 weeks (18 cycles; 541 or MPT (547 patients). primary end point was progression-free survival continuous...
PURPOSE To determine the efficacy and safety of 21 monthly cycles pamidronate therapy in patients with advanced multiple myeloma. PATIENTS AND METHODS Patients stage III myeloma at least one lytic lesion received either placebo or 90 mg intravenously administered as a 4-hour infusion for cycles. At study entry, were stratified according to whether they receive first-line (stratum 1) second-line 2) antimyeloma chemotherapy. Skeletal events (pathologic fracture, radiation surgery bone, spinal...
Pamidronate, an aminobisphosphonate, has been shown to lower the risk of skeletal complications associated with lytic bone lesions for up 1 year in women stage IV breast cancer who received chemotherapy. We studied long-term effectiveness and safety continued treatment intravenous pamidronate infusions 2 years.Three hundred eighty-two metastatic chemotherapy were randomly assigned receive either 90 mg or placebo intravenously every 3 4 weeks this double-blind, multicenter, parallel-group...
To assess whether pamidronate can reduce the frequency of skeletal morbidity in women with lytic bone metastases from breast cancer treated hormone therapy.Three hundred seventy-two who had at least one lesion and were receiving hormonal therapy randomized to receive 90 mg or placebo as a 2-hour intravenous infusion given double-blind fashion every 4 weeks for 24 cycles. Patients evaluated complications: pathologic fractures, spinal cord compression, irradiation surgery on bone,...
The long-term impact of thalidomide plus dexamethasone (thal/dex) as primary therapy for newly diagnosed multiple myeloma (MM) is unknown. goal this study was to compare versus placebo (placebo/dex)as MM.In double-blind, placebo-controlled trial, patients with untreated symptomatic MM were randomized thal/dex (arm A) or (dex) B). Patients in arm A received oral 50 mg daily, escalated 100 on day 15, and 200 from 1 cycle 2 (28-day cycles). Oral dex 40 administered days through 4, 9 12, 17 20...
Lenalidomide has shown significant antimyeloma activity in clinical studies. Oral melphalan, prednisone, and thalidomide have been regarded as the standard of care elderly multiple myeloma patients. We assessed dosing, efficacy, safety lenalidomide (MPR) newly diagnosed patients.Oral melphalan was administered doses ranging from 0.18 to 0.25 mg/kg on days 1 4, prednisone at a 2-mg/kg dose 5 10 mg 21, every 28 for nine cycles, followed by maintenance therapy with alone. Aspirin given...
To assess the safety, efficacy, and immunomodulatory effects of CC-4047 (Actimid; Celgene, San Diego, CA) in patients with relapsed or refractory myeloma.Twenty-four were treated a dose-escalating regimen oral CC-4047. Clinical responses adverse identified, peripheral T-cell subsets, serum cytokines, proangiogenic factors evaluated.CC-4047 was tolerated no serious nonhematologic events. All eligible for analysis. Toxicity criteria during initial 4 weeks study used to define maximum-tolerated...
The present study investigated the effect of renal impairment and hemodialysis on pharmacokinetics lenalidomide following a single 25-mg oral dose in 30 subjects aged 39 to 76 years. A was well tolerated by renally impaired subjects. Renal did not alter absorption, protein binding, or nonrenal elimination lenalidomide. Mean urinary recovery unchanged 84% with normal function (creatinine clearance [CL(Cr)] > 80 mL/min), it declined 69%, 38%, 43% mild (50 < = CL(Cr) moderate (30 50 severe...
The neural crest is a uniquely vertebrate cell type that gives rise to much of the craniofacial skeleton, pigment cells and peripheral nervous system, yet its specification diversification during embryogenesis are poorly understood. Zebrafish homozygous for lockjaw (low)mutation show defects in all these derivatives we low (allelic with montblanc) encodes zebrafish tfap2a, one small family transcription factors implicated epidermal development. A point mutation lowtruncates DNA binding...